Teva CEO Francis Urges UK To ‘Wake Up And Understand’ Life Sciences Potential

The UK Could ‘Compete With US West And East Coast Like No One Else In Europe’

The potential of the UK’s life sciences sector continues to be critically misunderstood and should be the cornerstone of both society and the economy, according to Teva’s CEO Richard Francis.  

Francis_Richard

Teva’s CEO Richard Francis believes the UK life sciences sector needs to “realize what’s under their nose,” as he stressed that the nation’s leaders were failing to grasp an opportunity that could see the country compete with the world-leading biotech hubs on the east and west coast of the US “like no other European country could.”

More from Innovation

More from In Vivo

The Scottish Biotech Harnessing The Power Of VLPs For Chronic Immune Conditions

 
• By 

Glen Clova Scientific is galvanizing virus-like particle technology with disruptive advances in manufacturing to treat immune-related dermatology conditions in often overlooked senile populations.

Podcast: The Future Of Immunotherapy

 
• By 

In this episode of the In Vivo podcast, Harvard immunologist and co-founder of early-stage biotech Corner Therapeutics, Jonathan Kagan, talks about harnessing the power of the innate immune system by weaponizing dendritic cells and creating immunotherapies that are safer and more durable.

Finding The Balance: First-In-Class Versus Best-In-Class

 
• By 

As pharmaceutical companies face a crowded and competitive landscape, the debate between being first-in-class or best-in-class is evergreen. This strategic choice impacts new product launches, with first-to-market therapies offering market share and brand recognition advantages, while best-in-class options can capture value through product differentiation and commercial execution. In Vivo talked to L.E.K. Consulting on how to make a product stand out from the crowd.